Recent Blog Articles

New cervical cancer vaccine highly promising, but questions remain

Updated: August 01, 2007

Many experts recommend vaccinating all preteen girls. Others urge caution.

In 2006, the FDA approved Gardasil, the first vaccine designed to prevent infection with the human papillomavirus (HPV). There are more than 100 strains of HPV, and 30 to 40 are sexually transmitted. Gardasil, made by the drug company Merck, targets strains 16 and 18, which are implicated in 70% of cervical cancers, and strains 6 and 11, which cause 90% of genital warts. The vaccine was approved on the basis of early results showing that it was virtually 100% effective in preventing infection by the targeted strains for up to 18 months.

To continue reading this article, you must log in.

Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.

  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »

I'd like to receive access to Harvard Health Online for only $4.99 a month.

Sign Me Up

Already a member? Login ».

Disclaimer:

As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.